BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
302.49
-8.30 (-2.67%)
At close: Apr 6, 2026, 4:00 PM EDT
303.64
+1.15 (0.38%)
After-hours: Apr 6, 2026, 6:24 PM EDT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 12 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $374.75, which forecasts a 23.89% increase in the stock price over the next year. The lowest target is $290 and the highest is $425.
Price Target: $374.75 (+23.89%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $340 | Buy | Initiates | $340 | +12.40% | Mar 27, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $420 → $290 | Strong Buy → Hold | Downgrades | $420 → $290 | -4.13% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $417 → $425 | Buy | Maintains | $417 → $425 | +40.50% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $400 → $412 | Strong Buy | Maintains | $400 → $412 | +36.20% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $400 → $410 | Strong Buy | Maintains | $400 → $410 | +35.54% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
45.27B
from 5.34B
Increased by 747.23%
Revenue Next Year
52.41B
from 45.27B
Increased by 15.78%
EPS This Year
3.45
from 2.47
Increased by 39.49%
EPS Next Year
4.94
from 3.45
Increased by 43.45%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.6B | 59.8B | |||
| Avg | 45.3B | 52.4B | |||
| Low | 42.0B | 46.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 809.5% | 32.2% | |||
| Avg | 747.2% | 15.8% | |||
| Low | 686.5% | 3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.40 | 7.07 | |||
| Avg | 3.45 | 4.94 | |||
| Low | 2.90 | 2.93 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 77.9% | 105.1% | |||
| Avg | 39.5% | 43.5% | |||
| Low | 17.4% | -15.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.